Johnson & Johnson Kicks Off Roadshow Ahead of Consumer Health Unit IPO
April 25, 2023
Trending News 🌥️
Johnson & Johnson ($NYSE:JNJ), the American multinational pharmaceutical, medical devices and consumer packaged goods manufacturer, is gearing up to start a roadshow ahead of their consumer health unit initial public offering (IPO). According to the Wall Street Journal, the company is planning to meet with investors in order to raise funds and get feedback on the IPO. Johnson & Johnson is one of the most iconic brands in the world, with a long history of providing quality healthcare products. Its portfolio of products covers a wide range of categories from pharmaceuticals to medical devices and consumer brands.
The company’s stock is listed on the New York Stock Exchange and is part of the Dow Jones Industrial Average. The expected IPO for Johnson & Johnson’s consumer health division will give investors the opportunity to buy shares in one of the world’s leading healthcare companies. With an IPO roadshow kicking off soon, investors should stay tuned for further updates on the company’s plans.
Stock Price
On Monday, Johnson & Johnson kicked off its roadshow in preparation for an upcoming initial public offering (IPO) for its consumer health unit. Interestingly, JOHNSON & JOHNSON stock opened at $162.7 and closed at $163.7, up 0.6% from the prior day’s closing price. This was done in order to attract potential investors and assess the value of the unit before it is floated on the stock market. The roadshow is part of a larger effort to unlock value for shareholders by spinning off the unit. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for JNJ. More…
| Total Revenues | Net Income | Net Margin |
| 96.26k | 12.72k | 12.6% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for JNJ. More…
| Operations | Investing | Financing |
| 23.42k | -6.19k | -18.02k |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for JNJ. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 179.23k | 108.96k | 26.89 |
Key Ratios Snapshot
Some of the financial key ratios for JNJ are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 5.2% | 3.6% | 23.6% |
| FCF Margin | ROE | ROA |
| 24.3% | 20.2% | 7.9% |
Analysis
GoodWhale has conducted an analysis of JOHNSON & JOHNSON’s wellbeing. Our Star Chart shows that the company is strong in dividend, profitability and weak in asset, growth. Having a health score of 8/10 with regard to its cashflows and debt, we can conclude that JOHNSON & JOHNSON is capable of paying off debt and funding future operations. We classify this company as a ‘cow’ – a type of company that has the track record of paying out consistent and sustainable dividends. Given these characteristics, we believe that JOHNSON & JOHNSON could be attractive to investors who are looking for a long-term, steady source of income. These investors may include retirement funds, long-term investors, and those who prioritize dividend yield over capital growth. More…
Peers
The competition between Johnson & Johnson and its competitors is fierce. AstraZeneca PLC, Pfizer Inc, and BioNTech SE are all major players in the pharmaceutical industry, and they are all vying for a piece of the pie. Johnson & Johnson is a well-established company with a long history of success, but its competitors are not to be underestimated. They are all large, well-funded companies with a lot to lose if they don’t win the competition.
– AstraZeneca PLC ($LSE:AZN)
AstraZeneca PLC is a biopharmaceutical company with a market cap of 152.13B as of 2022. The company focuses on the discovery, development, and commercialization of small molecule drugs in the areas of oncology, cardiovascular, and renal & metabolism. The company’s ROE for the year ended December 31, 2020 was -0.94%.
– Pfizer Inc ($NYSE:PFE)
Pfizer Inc is a pharmaceutical company with a market cap of 240.55B as of 2022. The company has a return on equity of 24.63%. Pfizer Inc is a research-based, global pharmaceutical company that discovers, develops, manufactures, and markets medicines for humans and animals. The company’s products include prescription and over-the-counter medicines, vaccines, and biologic therapies.
– BioNTech SE ($NASDAQ:BNTX)
BioNTech SE is a German biotech company founded in 2008 that focuses on the development of Innovation therapies against cancer and other serious diseases. The company has a market cap of 32.91B as of 2022 and a Return on Equity of 71.82%. BioNTech’s mission is to revolutionize the treatment of cancer and other serious diseases by leveraging the power of the immune system. The company is developing a portfolio of immunotherapy products based on its proprietary mRNA technology platform.
Summary
Johnson & Johnson is gearing up to launch an Initial Public Offering (IPO) of its consumer health unit. The company has begun its roadshow for the IPO, which is expected to be one of the largest this year. Investors are advised to review the company’s fundamentals prior to investments. Johnson & Johnson’s strong brand recognition is expected to attract strong investor interest.
The IPO will be closely watched by investors as it could provide insight on the health of the healthcare industry and its future prospects. Moreover, the IPO could generate significant returns for investors if successful. Investors interested in investing in Johnson & Johnson should consider the company’s track record, financials, and prospects prior to investing.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
